The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Clinical Cancer Research

• Publication date

  2000-04-01

• Fields of study

  Medicine

• Identifiers
  PMID 10778982
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells.

  1999cited by this paper
• Phase Ib trial of bryostatin 1 in patients with refractory malignancies.

  1998cited by this paper
• Effect of bryostatin 1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937).

  1998cited by this paper
• Taxol-induced p34cdc2 kinase activation and apoptosis inhibited by 12-O-tetradecanoylphorbol-13-acetate in human breast MCF-7 carcinoma cells.

  1998cited by this paper
• Chemotherapeutically induced DNA damage, ATP depletion, and the apoptotic biochemical cascade.

  1997cited by this paper
• Paclitaxel for breast cancer: the Memorial Sloan-Kettering Cancer Center experience.

  1997cited by this paper
• Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan.

  1997cited by this paper
• The role of Cdc2 feedback loop control in the DNA damage checkpoint in mammalian cells.

  1997cited by this paper
• Thermodynamic and structural analysis of microtubule assembly: the role of GTP hydrolysis.

  1997cited by this paper
• Role of acid/base homeostasis in the suppression of apoptosis in haemopoietic cells by v-Abl protein tyrosine kinase.

  1997cited by this paper
• Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply.

  1996cited by this paper
• The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1.

  1996cited by this paper
• Apoptosis induced in Jurkat cells by several agents is preceded by intracellular acidification.

  1996cited by this paper
• BCL-2 and MCL-1 expression in Chinese hamster ovary cells inhibits intracellular acidification and apoptosis induced by staurosporine.

  1996cited by this paper
• Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death.

  1996cited by this paper
• Inhibition of leukemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphorylation of cyclin-dependent kinase 2.

  1995cited by this paper
• A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.

  1995cited by this paper
• Bryostatin 1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: a 31P magnetic resonance spectroscopic study.

  1995cited by this paper
• Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma.

  1995cited by this paper
• Quantitative MRI of Gd‐DTPA uptake in tumors: Response to photo dynamic therapy

  1994cited by this paper
• The role of protein kinase C isoenzymes in the growth inhibition caused by bryostatin 1 in human A549 lung and MCF‐7 breast carcinoma cells

  1994cited by this paper
• Discrete signal processing of dynamic contrast‐enhanced MR imaging: Statistical validation and preliminary clinical application

  1994cited by this paper
• Successful treatment of human Waldenström's macroglobulinemia with combination biological and chemotherapy agents.

  1994cited by this paper
• Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells.

  1994cited by this paper
• A phase I study of intravenous bryostatin 1 in patients with advanced cancer.

  1993cited by this paper
• Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee.

  1993cited by this paper
• Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity.

  1992cited by this paper
• Determination of changes in tumor blood perfusion after hydralazine treatment by dynamic paramagnetic-enhanced magnetic resonance imaging.

  1992cited by this paper
• Quantitative changes in tumor metabolism, partial pressure of oxygen, and radiobiological oxygenation status postradiation.

  1992cited by this paper
• Response of osteosarcoma and Ewing sarcoma to preoperative chemotherapy: assessment with dynamic and static MR imaging and skeletal scintigraphy.

  1992cited by this paper
• Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum(II) by bryostatin 1.

  1992cited by this paper
• Successful treatment of murine melanoma with bryostatin 1.

  1991cited by this paper
• Universal control mechanism regulating onset of M-phase

  1990cited by this paper
• Response of osteosarcoma and Ewing sarcoma to preoperative chemotherapy: assessment with dynamic and static MR imaging and skeletal scintigraphy.

  1990cited by this paper
• Anaphase onset and dephosphorylation of mitotic phosphoproteins occur concomitantly.

  1989cited by this paper
• Co-induction of lymphokine synthesis by the antineoplastic bryostatins.

  1987cited by this paper
• Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin.

  1987cited by this paper
• Taxol effect on tubulin polymerization and associated guanosine 5'-triphosphate hydrolysis.

  1983cited by this paper
• Taxol stabilizes microtubules in mouse fibroblast cells.

  1980cited by this paper

• Anticancer Activity of the Marine-Derived Compound Bryostatin 1: Preclinical and Clinical Evaluation

  2025cites this paper
• Interplay between paclitaxel, gap junctions, and kinases: unraveling mechanisms of action and resistance in cancer therapy

  2024cites this paper
• The role of cuproptosis-related gene in the classification and prognosis of melanoma

  2022cites this paper
• Rebound increases in chemokines by CXCR2 antagonist in breast cancer can be prevented by PKCδ and PKCε activators.

  2021cites this paper
• Investigation of the anti-breast cancer efficacy and mechanisms of disulfiram

  2015cites this paper
• High-field small animal magnetic resonance oncology studies

  2014cites this paper
• Targeted treatments for metastatic esophageal squamous cell cancer.

  2013cites this paper
• Biological profile of the less lipophilic and synthetically more accessible bryostatin 7 closely resembles that of bryostatin 1.

  2013cites this paper
• Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells

  2013cites this paper
• Targeting apoptosis pathways by natural compounds in cancer: marine compounds as lead structures and chemical tools for cancer therapy.

  2013cites this paper
• Magnetic Resonance Spectroscopy of Cancer Metabolism and Response to Therapy

  2012cites this paper
• Structure-activity studies on the spiroketal moiety of a simplified analogue of debromoaplysiatoxin with antiproliferative activity.

  2012cites this paper
• The chemistry and biology of the bryostatins: potential PKC inhibitors in clinical development.

  2012cites this paper
• Role of the C8 gem-dimethyl group of bryostatin 1 on its unique pattern of biological activity.

  2012cites this paper
• Challenges to the development of bryostatin‐type anticancer drugs based on the activation mechanism of protein kinase Cδ

  2012cites this paper
• Protein Kinase C: An Attractive Target for Cancer Therapy

  2011cites this paper
• Combination Paclitaxel and Inhibitor of Nuclear Factor &kgr;B Activation Improves Therapeutic Outcome for Model Mice With Peritoneal Dissemination of Pancreatic Cancer

  2011cites this paper
• Terpinen-4-ol Induces Apoptosis in Human Nonsmall Cell Lung Cancer In Vitro and In Vivo

  2011cites this paper
• The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.

  2011cites this paper
• Approaches to the total synthesis of biologically active natural products: studies directed towards bryostatins

  2010cites this paper
• A Study Of Cell Growth, Division And Programmed Differentiation By Simulation And Experiments.

  2010cites this paper
• The bryostatin 1 A-ring acetate is not the critical determinant for antagonism of phorbol ester-induced biological responses.

  2009cites this paper
• Substitution on the A-ring confers to bryopyran analogues the unique biological activity characteristic of bryostatins and distinct from that of the phorbol esters.

  2009cites this paper
• Anticancer drugs discovery and development from marine organism.

  2009cites this paper
• Phase II Study of Paclitaxel Plus the Protein Kinase C Inhibitor Bryostatin-1 in Advanced Pancreatic Carcinoma

  2009cites this paper
• Targeting protein kinase C (PKC) in physiology and cancer of the gastric cell system.

  2008cites this paper
• Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer

  2008cites this paper
• Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells

  2008cites this paper
• Protein Kinase C: A Target for Therapy in Pancreatic Cancer

  2008cites this paper
• Targeting the protein kinase C family: are we there yet?

  2008cites this paper
• Targeting the protein kinase C family: are we there yet?

  2007cites this paper
• Measuring tumor response and shape change on CT: esophageal cancer as a paradigm.

  2006cites this paper
• A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma

  2006cites this paper
• Cyclin-dependent kinases as targets for cancer therapy.

  2006cites this paper
• Drugs for Lung Cancer Treatment

  2006cites this paper
• Cyclin-Dependent Kinase Inhibitors in Combination Chemotherapy

  2005cites this paper
• Spectral and Temporal Near-Infrared Imaging of Ex Vivo Cancerous and Normal Human Breast Tissues

  2005cites this paper
• Targeting the cell cycle: a new approach to cancer therapy.

  2005cites this paper
• Aquaculture of "non-food organisms" for natural substance production.

  2005cites this paper
• Development of Noninvasive Methods for Monitoring Tissue Engineered Constructs using Nuclear Magnetic Resonance

  2004cites this paper
• The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts.

  2004cites this paper
• Novel therapeutic targets in squamous cell carcinoma of the head and neck.

  2004cites this paper
• Single dose of the antivascular agent, ZD6126 (N-acetylcolchinol-O-phosphate), reduces perfusion for at least 96 hours in the GH3 prolactinoma rat tumor model.

  2004cites this paper
• The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor zenografts

  2004cites this paper
• Novel Anticancer Agents in Clinical Development

  2003cites this paper
• A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer.

  2003cites this paper
• Marine pharmacology in 2000: Antitumor and cytotoxic compounds

  2003cites this paper
• A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: A Gynecologic Oncology Group Study

  2003cites this paper
• Detecting early response to cyclophosphamide treatment of RIF‐1 tumors using selective multiple quantum spectroscopy (SelMQC) and dynamic contrast enhanced imaging

  2003cites this paper
• Induction of tumor necrosis factor by bryostatin 1 is involved in synergistic interactions with paclitaxel in human myeloid leukemia cells.

  2003cites this paper
• Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma

  2003cites this paper
• Bryostatin-1: A Novel PKC Inhibitor in Clinical Development

  2003cites this paper
• A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma

  2003cites this paper
• Cell cycle perturbations and radiosensitization effects in a human prostate cancer cell line

  2003cites this paper
• Novel targets for lung cancer therapy: part I.

  2002cites this paper
• Administration of a phorbol ester to patients with hematological malignancies: preliminary results from a phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetate.

  2002cites this paper
• Signaling Inhibitors in the Treatment of Prostate Cancer

  2002cites this paper
• A Phase II Trial of Bryostatin-1 in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

  2002cites this paper
• Die Bedeutung klinischer Studien für die Therapieoptimierung des Analkarzinoms

  2002cites this paper
• Die Bedeutung klinischer Studien für die Therapieoptimierung des Analkarzinoms

  2002cites this paper
• CHAPTER 12 – BIOSYNTHETIC PRODUCTS FOR ANTICANCER DRUG DESIGN AND TREATMENT: THE BRYOSTATINS

  2002cites this paper
• The clinical development of the bryostatins

  2002cites this paper
• Protein kinase C isozymes, novel phorbol ester receptors and cancer chemotherapy.

  2001cites this paper
• A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma

  2001cites this paper
• Paclitaxel and docetaxel in prostate cancer.

  2001cites this paper
• Novel pharmacological agents in clinical development for solid tumours

  2001cites this paper
• Cell cycle-mediated drug resistance: an emerging concept in cancer therapy.

  2001cites this paper
• Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development.

  2000cites this paper
• The relevance of drug sequence in combination chemotherapy.

  2000cites this paper